BioSpace News Archive

electroCore, Inc. announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.

Heart Test Laboratories, Inc. d/b/a HeartSciences today announced that Company CEO, Andrew Simpson, will present at Maxim Group’s Virtual Tech Conference Series: Emerging Growth in A.I on Wednesday, September 27th, 2023, at 10:30 a.m. ET.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, OrthoPediatrics was a proud sponsor of the 58th Annual Meeting for the Scoliosis Research Society held in Seattle, Washington, on September 6-9th.

Biora Therapeutics, Inc today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Prostate cancer management reached a new pinnacle of precision with Bot Image’s ProstatID using Bi-parametric MRI (bpMRI).

Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the publication of new preclinical data demonstrating linsitinib reduced pathologic bone marrow activity in a mouse model of TED.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors.

Arcutis Biotherapeutics, Inc. announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short.

Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262 in subjects with chronic inducible urticaria.

Reviva Pharmaceuticals Holdings, Inc. announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study.